NICE does not recommend Perjeta + Herceptin combination to treat HER2-positive early breast cancer. Roche.
The National Institute for Health and Care Excellence (NICE) released draft guidance recommending against NHS use of combination Perjeta and Herceptin (pertuzumab + trastuzumab) and chemotherapy in HER2-positive early breast cancer patients who face a high risk of their cancer returning after surgery.
A NICE evaluation committee concluded that adding Perjeta to the Herceptin-chemotherapy regimen “made only a small difference in the proportion of people who remained free of invasive disease" and particularly required more data on its effect on overall survival in people with HER2-positive breast cancer..
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.